Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

VACCINE RESPONSES IN TRALOKINUMAB-TREATED ATOPIC DERMATITIS ECZTRA 5

Intervention/treatment:
TRALOKINUMAB (CAT-354)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
LP0162-1341
Control number:
216656
Status:
Closed
Approved:
June 19, 2018
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03562377
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 54 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Disclosure
Organization
LEO Pharma A/S
Phone:
+45
Extension 44945888
Sponsor
LEO PHARMA AS

Locations

Alberta

LEO Pharma Investigational Site
Edmonton, Alberta, T5K 1X3
LEO Pharma Investigational Site
Edmonton, Alberta, T6G 1C3

British Columbia

LEO Pharma Investigational Site
Vancouver, British Columbia, V6H 4E1

Newfoundland and Labrador

LEO Pharma Investigational Site
St. John's, Newfoundland and Labrador, A1A 4Y3

Ontario

LEO Pharma Investigational Site
Hamilton, Ontario, L8S 1G5
LEO Pharma Investigational Site
London, Ontario, N6H 5L5
LEO Pharma Investigational Site
Oakville, Ontario, L6J 7W5
LEO Pharma Investigational Site
Peterborough, Ontario, K9J 5K2
LEO Pharma Investigational Site
Richmond Hill, Ontario, L4B 1A5
LEO Pharma Investigational Site
Toronto, Ontario, M4V 1R2
LEO Pharma Investigational Site
Windsor, Ontario, N8X 2G1

Quebec

LEO Pharma Investigational Site
Verdun, Quebec, H4G 3E7

Results

See the results from the trial NCT03562377. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?